Skip to main content
. 2016 Sep 28;44(20):9519–9529. doi: 10.1093/nar/gkw867

Figure 3.

Figure 3.

MALAT1 RNA in P7 liver, kidney, inner ear and brain after intra-amniotic cavity dosing with ASO-MALAT1. (A) Quantitation of the average relative quantity (RQ) of MALAT1 RNA normalized to β-actin RNA (ACTB) in the liver, kidney, inner ear and brain from P7 mice subjected to intra-amniotic cavity microinjection of 10, 40 or 80 μg (n = 5, 3, 6, respectively) of ASO-MALAT1 or ASO-C (n = 3). Error bars represent s.e.m., *P < 0.05, **P < 0.01, ****P < 0.0001, one-tail, two-sample t-test (B) The same data as shown in (A) with ASO-MALAT1-treated samples normalized to ASO-C-treated samples which are represented as 100% (dotted line). Error bars represent s.e.m, *P < 0.05, ***P < 0.001 one-way ANOVA with Bonferroni's Multiple Comparison test.